Presentation is loading. Please wait.

Presentation is loading. Please wait.

Xueli Zhang, PhD, Yamin Liu, PhD, Hua Shao, MD, PhD, Xiao Zheng, PhD 

Published byΟἰδίπους Δασκαλόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "Xueli Zhang, PhD, Yamin Liu, PhD, Hua Shao, MD, PhD, Xiao Zheng, PhD "— Presentation transcript:

1 Obesity Paradox in Lung Cancer Prognosis: Evolving Biological Insights and Clinical Implications 
Xueli Zhang, PhD, Yamin Liu, PhD, Hua Shao, MD, PhD, Xiao Zheng, PhD  Journal of Thoracic Oncology  Volume 12, Issue 10, Pages (October 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Potential biological mechanisms contributing to the obesity paradox in lung cancer. Factors that may contribute to better prognosis in lung cancer include the following: (1) patients with metabolically healthy obesity or physiological fitness may not suffer from the detrimental effects of obesity-associated metabolic disturbance; (2) adipose tissue may provide greater physiological and nutritional reserves, thereby prolonging life by slowing the progress of cancer cachexia; and (3) some adipokines from the adipose tissue may produce tumor-suppressing effects and, therefore, survival advantages. However, the presence of cachexia and presence of sarcopenia, which are characterized by massive and progressive muscle and fat loss, are established as predictors of poor prognosis of lung cancer. These biological mechanisms may partially explain the inverse relationship between body mass index (BMI) and lung cancer outcome. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Xueli Zhang, PhD, Yamin Liu, PhD, Hua Shao, MD, PhD, Xiao Zheng, PhD "

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages 1862-1863.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21  Marie Florescu,
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Karin J. C. Sanders, MD, Lizza E. Hendriks, MD, Esther G. C

Karin J. C. Sanders, MD, Lizza E. Hendriks, MD, Esther G. C
Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,
The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer  Boris Sepesi, MD, Kathryn A. Gold, MD,

The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer  Boris Sepesi, MD, Kathryn A. Gold, MD,
Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller  Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller  Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 
Frank Detterbeck, MD  Journal of Thoracic Oncology 

Frank Detterbeck, MD  Journal of Thoracic Oncology 
Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K
Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.
Stefano Occhipinti, PhD, Jeff Dunn, PhD, Dianne L

Stefano Occhipinti, PhD, Jeff Dunn, PhD, Dianne L

Similar presentations

Ads by Google